和誉-B:默克根据授权协议行使匹米替尼的全球选择权

格隆汇
01 Apr

格隆汇4月1日丨和誉-B(02256.HK)发布公告,2025年4月1日,和誉医药宣布,默克已根据双方于2023年12月签订的授权协议,行使匹米替尼(ABSK021)的全球商业化选择权,行权费用为8500万美元。该进展标志着双方合作的进一步深化,凸显了双方对持续推进匹米替尼的坚定承诺和信心。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10